NEW YORK (GenomeWeb) — Novacyt today reported revenues of €7 million ($8.1 million) for the first half of 2018, unchanged from the year-ago period as gains in the company's Lab21 protein diagnostics and Primerdesign molecular diagnostics units were offset by weak demand for its Novaprep cytology products.